

NeurAxon, Inc. to Present at the BIO National Venture Conference April 1, 2009

WALTHAM, Mass. March 27, 2009 – NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company's Chief Executive Officer, will present at the BIO National Venture Conference taking place March 31 – April 1, 2009 in Boston, MA.

The NeurAxon presentation will be delivered on Wednesday, April 1, 2009 at 10:35am Eastern Time at the Sheraton Boston Hotel.

Dr. Bloch will provide an overview of NeurAxon and its portfolio of novel, proprietary pain therapeutics, including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in development for acute migraine.

About NeurAxon Inc.

NeurAxon Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Contact:

Chris Erdman
MacDougall Biomedical Communications
781-235-3060, ext. 14